Literature DB >> 17320916

Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice.

Yann S Mineur1, Oli Somenzi, Marina R Picciotto.   

Abstract

The nicotine in tobacco is thought to modulate neuronal systems regulating mood. Moreover, it appears possible that blockade rather than activation of beta2-containing (beta2*) nicotinic acetylcholine receptors (nAChRs) may lead to antidepressant-like effects. We used cytisine, a partial agonist of alpha4/beta2*nAChRs and a full agonist at alpha3/beta4*nAChRs, in several tests of antidepressant efficacy. Further, we used c-fos expression to identify potential neurobiological correlates of the antidepressant-like effects of cytisine. Cytisine had antidepressant-like effects in several animal models of antidepressant efficacy. In addition, immunohistochemical analyses indicated that cytisine could reduce c-fos immunoreactivity in the basolateral amygdala by approximately 50%. These data show that cytisine acts like classical antidepressants in rodent models of antidepressant efficacy. In addition, cytisine's ability to block alpha4/beta2*nAChRs may be responsible for its antidepressant-like properties, and these may be mediated through a reduction of neuronal activity in the basolateral amygdala. These studies also suggest that both antagonists and partial agonists of alpha4/beta2*nAChRs would be interesting targets for the development of novel antidepressant drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17320916      PMCID: PMC1959230          DOI: 10.1016/j.neuropharm.2007.01.006

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  36 in total

1.  Behavioral and neuroanatomical characterization of FVB/N inbred mice.

Authors:  Yann S Mineur; Wim E Crusio
Journal:  Brain Res Bull       Date:  2002-01-01       Impact factor: 4.077

Review 2.  Assessing antidepressant activity in rodents: recent developments and future needs.

Authors:  John F Cryan; Athina Markou; Irwin Lucki
Journal:  Trends Pharmacol Sci       Date:  2002-05       Impact factor: 14.819

Review 3.  Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure.

Authors:  C L Gentry; R J Lukas
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2002-08

Review 4.  Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders.

Authors:  W C Drevets
Journal:  Curr Opin Neurobiol       Date:  2001-04       Impact factor: 6.627

5.  Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse.

Authors:  Yann S Mineur; Frans Sluyter; Sanne de Wit; Ben A Oostra; Wim E Crusio
Journal:  Hippocampus       Date:  2002       Impact factor: 3.899

Review 6.  Desensitization of neuronal nicotinic receptors.

Authors:  Michael W Quick; Robin A J Lester
Journal:  J Neurobiol       Date:  2002-12

7.  Sex differences in response to oral amitriptyline in three animal models of depression in C57BL/6J mice.

Authors:  B J Caldarone; K Karthigeyan; A Harrist; J G Hunsberger; E Wittmack; S L King; P Jatlow; M R Picciotto
Journal:  Psychopharmacology (Berl)       Date:  2003-07-15       Impact factor: 4.530

Review 8.  Nicotine dependence and psychiatric disorders.

Authors:  Rafael J Salín-Pascual; Natasha V Alcocer-Castillejos; Gabriel Alejo-Galarza
Journal:  Rev Invest Clin       Date:  2003 Nov-Dec       Impact factor: 1.451

Review 9.  In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice.

Authors:  J F Cryan; C Mombereau
Journal:  Mol Psychiatry       Date:  2004-04       Impact factor: 15.992

10.  Chronic desipramine alters stress-induced behaviors and regional expression of the immediate early gene, c-fos.

Authors:  C H Beck; H C Fibiger
Journal:  Pharmacol Biochem Behav       Date:  1995 Jun-Jul       Impact factor: 3.533

View more
  66 in total

1.  Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity.

Authors:  Li-Fang Yu; Werner Tückmantel; J Brek Eaton; Barbara Caldarone; Allison Fedolak; Taleen Hanania; Dani Brunner; Ronald J Lukas; Alan P Kozikowski
Journal:  J Med Chem       Date:  2012-01-04       Impact factor: 7.446

Review 2.  Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature.

Authors:  Noah S Philip; Linda L Carpenter; Audrey R Tyrka; Lawrence H Price
Journal:  Psychopharmacology (Berl)       Date:  2010-07-08       Impact factor: 4.530

Review 3.  Examining antidepressant drug response by smoking status: why is it important and how often is it done?

Authors:  Andrea H Weinberger; Sherry A McKee; Marina R Picciotto; Carolyn M Mazure
Journal:  J Psychopharmacol       Date:  2010-12-17       Impact factor: 4.153

4.  Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder.

Authors:  Aybala Saricicek; Irina Esterlis; Kathleen H Maloney; Yann S Mineur; Barbara M Ruf; Anjana Muralidharan; Jason I Chen; Kelly P Cosgrove; Rebecca Kerestes; Subroto Ghose; Carol A Tamminga; Brian Pittman; Frederic Bois; Gilles Tamagnan; John Seibyl; Marina R Picciotto; Julie K Staley; Zubin Bhagwagar
Journal:  Am J Psychiatry       Date:  2012-08       Impact factor: 18.112

5.  Modulation of ethanol drinking-in-the-dark by mecamylamine and nicotinic acetylcholine receptor agonists in C57BL/6J mice.

Authors:  Linzy M Hendrickson; Rubing Zhao-Shea; Andrew R Tapper
Journal:  Psychopharmacology (Berl)       Date:  2009-02-27       Impact factor: 4.530

Review 6.  Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system.

Authors:  Antoine Taly; Pierre-Jean Corringer; Denis Guedin; Pierre Lestage; Jean-Pierre Changeux
Journal:  Nat Rev Drug Discov       Date:  2009-09       Impact factor: 84.694

Review 7.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

8.  Nicotinic receptor ligands reduce ethanol intake by high alcohol-drinking HAD-2 rats.

Authors:  Richard L Bell; Bill J A Eiler; Jason B Cook; Shafiqur Rahman
Journal:  Alcohol       Date:  2009-12       Impact factor: 2.405

9.  Pharmacokinetics and brain penetration of LF-3-88, (2-[5-[5-(2(S)-azetidinylmethoxyl)-3-pyridyl]-3-isoxazolyl]ethanol), a selective α4β2-nAChR partial agonist and promising antidepressant.

Authors:  Yang Yuan; Li-Fang Yu; Xi Qiu; Alan P Kozikowski; Richard B van Breemen
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-11-23       Impact factor: 3.205

10.  Perspective: Translational studies on glutamate and dopamine neurocircuitry in addictions: implications for addiction treatment.

Authors:  Evelyn K Lambe; Tony P George
Journal:  Neuropsychopharmacology       Date:  2008-11-05       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.